A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
Public ClinicalTrials.gov record NCT02406209. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, multi-center, investigator masked, comparator controlled study. The purpose of this study is to determine the efficacy and safety of NS2 in patients with non-infectious acute anterior uveitis. Subjects will be randomized 1:1:1 to receive multiple doses of NS2 0.5%, NS2 0.5% and Pred Forte® 1%, or Pred Forte® 1%. Free aldehydes are thought to be related to inflammatory diseases such as uveitis. NS2, a small molecule aldehyde trap, may decrease inflammation by lowering aldehyde levels.
Study identification
- NCT ID
- NCT02406209
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2015 (Type not available)
- Primary completion
- Apr 2016 (Actual)
- Completion
- Apr 2016 (Actual)
- Last update posted
- Mar 27, 2023
2015 – 2016
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hull Eye Center | Lancaster | California | 93534 | — |
| Colorado Retina Associates,PC | Golden | Colorado | 80401 | — |
| Eye Center of Southern Connecticut | Hamden | Connecticut | 06518-3144 | — |
| Bascom Palmer Eye Institute | Plantation | Florida | 33324 | — |
| Valley Eye Physicians & Surgeons | Ayer | Massachusetts | 01940 | — |
| Ophthalmic Consultants of Boston | Boston | Massachusetts | 02114 | — |
| Massachusetts Eye Research and Surgery Institution (MERSI) | Waltham | Massachusetts | 02451 | — |
| Oakland Ophthalmic Surgery | Birmingham | Michigan | 48009 | — |
| Lifelong Vision Foundation | Chesterfield | Missouri | 63017 | — |
| Tauber Eye Center | Kansas City | Missouri | 64111 | — |
| UNMC Stanley Truhlsen Eye Institute | Omaha | Nebraska | 68106 | — |
| Metropolitan Eye Research & Surgery Institute | Palisades Park | New Jersey | 07650 | — |
| Mid-Atlantic Retina | Philadelphia | Pennsylvania | 19107 | — |
| Houston Eye Associates | Houston | Texas | 77025 | — |
| Virginia Eye Consultants | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02406209, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 27, 2023 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02406209 live on ClinicalTrials.gov.